Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review

Review (10 RCTs; n=5765) found that immunotherapy plus chemotherapy, as a first line treatment, has better survival outcomes and response rates vs immunotherapy alone in patients with PD-L1 expression in at least 50% of tumour cells.

Source:

BMJ Open